Small molecules continue to play a major part in pharmaceutical development, but increasing molecular complexity, accelerated timelines, and evolving manufacturing and regulatory requirements are creating new challenges for the industry.
In this GEN Podcast – part 2 in a 3-part series -- a trio of experts from SK Pharmteco discuss how CDMOs are helping biopharma companies navigate critical areas including scale-up, technology transfer, advanced manufacturing, automation, sustainability, the emergence of AI, and supply chain reliability. The discussion explores practical strategies for improving development efficiency while supporting quality, scalability, and long-term commercial success.
Guest Speakers
Steve Barr, PhD -- Head of Small Molecule Business Unit and VP Global Alliances, SK Pharmteco.
Darryl Ratty -- Executive Director of Global ESG (Environmental, Social and Governance), SK Pharmteco.
Bill Dubay -- VP, Global Research and Development, SK Pharmteco.
Podden och tillhörande omslagsbild på den här sidan tillhör
Genetic Engineering & Biotechnology News (GEN). Innehållet i podden är skapat av Genetic Engineering & Biotechnology News (GEN) och inte av,
eller tillsammans med, Poddtoppen.